Obesity is a well-established risk factor for breast cancer, and scientists are increasingly exploring how metabolic interventions might influence cancer development and progression. Amanda Kosinskas, a Ph.D. candidate at the University of Michigan and lead author of the recent study, told the New York Post that while these findings are still preliminary, they may point toward a new therapeutic path. The results in mice show that these anti-obesity drugs could potentially lower the risk or severity of obesity-related cancers and enhance the effectiveness of existing cancer treatments.
